MGMT and soft tissue sarcoma: Aiming at optimizing the use of dacarbazine in soft tissue sarcomas and to find out if the methylation of MGMT correlates with clinical response, the assessment of MGMT promoter methylation may be explored as a possible predictive factor for the identification of patients who may better benefit from chemotherapy.